Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
151TiP TANGENT: A phase III, global, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor
Emanuela Palmerini, S. Veltkamp, H. Gelderblom, Javier Martín‐Broto, A. Sebio García, M. Van de Sande, Gabriel Tinoco, Elyse Seltzer, Matthew Davies, Jean Yves Blay (2025). 151TiP TANGENT: A phase III, global, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor. , 10, DOI: https://doi.org/10.1016/j.esmoop.2025.104464.
Article33 days agoA phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).
Hans Gelderblom, Emanuela Palmerini, Jean Yves Blay, Michiel A. J. van de Sande, Javier Martín‐Broto, Raúl Terés, M. B. Davies, Elyse Seltzer, S. Veltkamp, Gabriel Tinoco (2025). A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps11584.
Article33 days ago